CD8A and neoplasm: Withdrawal of Kras<sup>G12D</sup> results in >90% tumor regression by day 7, accompanied by infiltration and enrichment of activated CD8<sup>+</sup> T cells, shown by IHC, co-IF staining, and single-cell RNA-Seq.